Drug
SB17170
SB17170 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Recruiting2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
recruiting250%
completed250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_1
SB17170 Phase 1 Clinical Trial in Solid Tumors
NCT05522868
completedphase_1
A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects
NCT06846684
recruitingphase_2
SB17170 Phase 2 Trial in IPF Patients
NCT06747923
completedphase_1
SB17170 Phase1 Trial in Healthy Volunteer
NCT05795192
Clinical Trials (4)
Showing 4 of 4 trials
NCT05522868Phase 1
SB17170 Phase 1 Clinical Trial in Solid Tumors
NCT06846684Phase 1
A Open-label, Drug-Drug Interaction With SB_MDZ in Healty Adult Subjects
NCT06747923Phase 2
SB17170 Phase 2 Trial in IPF Patients
NCT05795192Phase 1
SB17170 Phase1 Trial in Healthy Volunteer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4